Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, R...

FDA Drug Recall #D-0541-2025 — Class II — June 30, 2025

Recall Summary

Recall Number D-0541-2025
Classification Class II — Moderate risk
Date Initiated June 30, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Cipla USA, Inc.
Location Warren, NJ
Product Type Drugs
Quantity 13,680 ampoules

Product Description

Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)

Reason for Recall

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Distribution Pattern

Distributed Nationwide in the USA

Lot / Code Information

Batch # 4IA0505, Exp 09/31/2026

Other Recalls from Cipla USA, Inc.

Recall # Classification Product Date
D-0381-2026 Class III Nilotinib Capsules, 150 mg per capsule, package... Feb 18, 2026
D-0382-2026 Class III Nilotinib Capsules, 200 mg per capsule, package... Feb 18, 2026
D-0290-2026 Class II Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per... Jan 2, 2026
D-0291-2026 Class III Diclofenac Sodium Topical Gel, 1%, NET WT 100 g... Dec 22, 2025
D-0226-2026 Class II Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tab... Nov 14, 2025

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.